NYSEAMERICAN:SYNSynthetic Biologics Competitors & Alternatives

Synthetic Biologics (NYSEAMERICAN:SYN) and AmpliPhi Biosciences (NASDAQ:ARMP) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, earnings, profitability, institutional ownership, dividends and risk.

Profitability

This table compares Synthetic Biologics and AmpliPhi Biosciences' net margins, return on equity and return on assets.

Analyst Recommendations

This is a summary of current recommendations and price targets for Synthetic Biologics and AmpliPhi Biosciences, as provided by MarketBeat.com.

Synthetic Biologics presently has a consensus price target of $1.3750, indicating a potential upside of 134.24%. Given Synthetic Biologics' higher probable upside, analysts clearly believe Synthetic Biologics is more favorable than AmpliPhi Biosciences.

Valuation & Earnings

This table compares Synthetic Biologics and AmpliPhi Biosciences' revenue, earnings per share and valuation.

Summary

Synthetic Biologics beats AmpliPhi Biosciences on 2 of the 2 factors compared between the two stocks.

Armata Pharmaceuticals (NYSEAMERICAN:ARMP) and Synthetic Biologics (NYSEAMERICAN:SYN) are both small-cap health technology companies, but which is the superior business? We will compare the two businesses based on the strength of their earnings, analyst recommendations, risk, institutional ownership, valuation, dividends and profitability.

Earnings and Valuation

This table compares Armata Pharmaceuticals and Synthetic Biologics' gross revenue, earnings per share (EPS) and valuation.

Analyst Ratings

This is a breakdown of recent recommendations for Armata Pharmaceuticals and Synthetic Biologics, as reported by MarketBeat.

Armata Pharmaceuticals currently has a consensus target price of $7.3333, indicating a potential upside of 100.91%. Synthetic Biologics has a consensus target price of $1.3750, indicating a potential upside of 134.24%. Given Synthetic Biologics' higher probable upside, analysts clearly believe Synthetic Biologics is more favorable than Armata Pharmaceuticals.

Profitability

This table compares Armata Pharmaceuticals and Synthetic Biologics' net margins, return on equity and return on assets.

Synthetic Biologics (NYSEAMERICAN:SYN) and ContraVir Pharmaceuticals (NYSE:HEPA) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, analyst recommendations, risk, valuation, institutional ownership, profitability and dividends.

Analyst Recommendations

This is a summary of recent ratings for Synthetic Biologics and ContraVir Pharmaceuticals, as reported by MarketBeat.com.

Synthetic Biologics presently has a consensus price target of $1.3750, indicating a potential upside of 134.24%. Given Synthetic Biologics' higher probable upside, research analysts clearly believe Synthetic Biologics is more favorable than ContraVir Pharmaceuticals.

Profitability

This table compares Synthetic Biologics and ContraVir Pharmaceuticals' net margins, return on equity and return on assets.

Earnings & Valuation

This table compares Synthetic Biologics and ContraVir Pharmaceuticals' gross revenue, earnings per share (EPS) and valuation.

Summary

Synthetic Biologics beats ContraVir Pharmaceuticals on 2 of the 2 factors compared between the two stocks.

Can-Fite Biopharma (NASDAQ:CANF) and Synthetic Biologics (NYSEAMERICAN:SYN) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, risk, institutional ownership, profitability, earnings, dividends and valuation.

Analyst Ratings

This is a breakdown of recent ratings and target prices for Can-Fite Biopharma and Synthetic Biologics, as provided by MarketBeat.

Synthetic Biologics has a consensus price target of $1.3750, indicating a potential upside of 134.24%. Given Synthetic Biologics' higher possible upside, analysts plainly believe Synthetic Biologics is more favorable than Can-Fite Biopharma.

Profitability

This table compares Can-Fite Biopharma and Synthetic Biologics' net margins, return on equity and return on assets.

Earnings and Valuation

This table compares Can-Fite Biopharma and Synthetic Biologics' revenue, earnings per share (EPS) and valuation.

Summary

Synthetic Biologics beats Can-Fite Biopharma on 2 of the 2 factors compared between the two stocks.

Biopharmx (NYSEAMERICAN:BPMX) and Synthetic Biologics (NYSEAMERICAN:SYN) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, profitability, institutional ownership, valuation, earnings and dividends.

Earnings & Valuation

This table compares Biopharmx and Synthetic Biologics' revenue, earnings per share (EPS) and valuation.

Profitability

This table compares Biopharmx and Synthetic Biologics' net margins, return on equity and return on assets.

Analyst Recommendations

This is a breakdown of recent ratings and price targets for Biopharmx and Synthetic Biologics, as provided by MarketBeat.com.

Biopharmx presently has a consensus target price of $12.00, indicating a potential upside of 548.65%. Synthetic Biologics has a consensus target price of $1.3750, indicating a potential upside of 134.24%. Given Biopharmx's higher possible upside, research analysts clearly believe Biopharmx is more favorable than Synthetic Biologics.

Summary

Synthetic Biologics beats Biopharmx on 2 of the 3 factors compared between the two stocks.

Synthetic Biologics (NYSEAMERICAN:SYN) and CAN-FITE BIOPHA/S (NYSEAMERICAN:CANF) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, earnings, analyst recommendations, valuation, profitability, dividends and risk.

Earnings & Valuation

This table compares Synthetic Biologics and CAN-FITE BIOPHA/S's top-line revenue, earnings per share and valuation.

Profitability

This table compares Synthetic Biologics and CAN-FITE BIOPHA/S's net margins, return on equity and return on assets.

Analyst Ratings

This is a summary of current ratings for Synthetic Biologics and CAN-FITE BIOPHA/S, as reported by MarketBeat.com.

Synthetic Biologics currently has a consensus price target of $1.3750, suggesting a potential upside of 134.24%. CAN-FITE BIOPHA/S has a consensus price target of $5.00, suggesting a potential upside of 132.56%. Given Synthetic Biologics' higher possible upside, equities research analysts plainly believe Synthetic Biologics is more favorable than CAN-FITE BIOPHA/S.

Institutional & Insider Ownership

5.1% of CAN-FITE BIOPHA/S shares are held by institutional investors. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

Synthetic Biologics beats CAN-FITE BIOPHA/S on 2 of the 3 factors compared between the two stocks.